The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients with positive results of viral testing, and who have a high chance of getting severe COVID-19 in Korea.
This study is seeking participants who are:
Adults and children (12 years of age and older weighing at least 40 kgs) with positive results of viral testing.
Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death.
Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label.
Patients who have signed informed consent documents after understanding all the important parts of the study.
All participants are treated according to routine medical practice and there are no scheduled visits required by this study. All participants will be studied for a follow-up period of 28 days from the last PAXLOVID treatment to understand the safety and the effectiveness of treatment.
Closest Location
NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier.
Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.
Condition
COVID-19
Sex
Male or Female
Age
12+ years